个人科研网厅 | | 帮助
高级检索
当前位置： 首页 > 详情页

Treating advanced non-small-cell lung cancer in Chinese patients: focus on icotinib

| 导出 | |

文献详情

资源类型：
WOS体系：
Pubmed体系：

收录情况： ◇ SCIE

作者：
Liang, Jun-Li[1] * ; Ren, Xiao-Cang[2] ; Lin, Qiang[2,*1] ;
机构： [1]Department of Radiation Oncology, Hebei Medical University Fourth Hospital, Shijiazhuang, People’s Republic of China [2]Department of Oncology, North China Petroleum Bureau General Hospital of Hebei Medical University, Renqiu, Hebei Province, People’s Republic of China
出处：
DOI： 10.2147/OTT.S49233
ISSN：

关键词： targeted therapy EGFR-TKI NSCLC

摘要：
Icotinib hydrochloride is an orally administered small-molecule reversible tyrosine kinase inhibitor that has been independently researched and developed and has independent intellectual property rights in the People's Republic of China. Clinical trials have demonstrated that the response to icotinib among advanced non-small-cell lung cancer (NSCLC) patients who received at least one platinum-based chemotherapy regimen was not inferior to gefitinib. Since being launched August 2011 in the People's Republic of China, icotinib has been widely used in clinics, and has become an important treatment option for Chinese patients with advanced NSCLC. The present study presents the Phase I, II, and III clinical trials of icotinib and discusses current clinical applications in the People's Republic of China and future research directions.

语种：
外文
被引次数：
WOS：
PubmedID：
中科院分区：
出版当年[2014]版：
大类 | 4 区 医学
小类 | 4 区 生物工程与应用微生物 4 区 肿瘤学
最新[2025]版：
大类 | 4 区 医学
小类 | 4 区 生物工程与应用微生物 4 区 肿瘤学
JCR分区：
出版当年[2014]版：
Q2 BIOTECHNOLOGY & APPLIED MICROBIOLOGY Q3 ONCOLOGY
最新[2023]版：
Q3 BIOTECHNOLOGY & APPLIED MICROBIOLOGY Q3 ONCOLOGY

影响因子： 最新[2023版] 最新五年平均 出版当年[2014版] 出版当年五年平均 出版前一年[2013版] 出版后一年[2015版]

第一作者：
第一作者机构： [1]Department of Radiation Oncology, Hebei Medical University Fourth Hospital, Shijiazhuang, People’s Republic of China
通讯作者：
通讯机构： [2]Department of Oncology, North China Petroleum Bureau General Hospital of Hebei Medical University, Renqiu, Hebei Province, People’s Republic of China [*1]Department of Oncology, North China Petroleum Bureau General Hospital of Hebei Medical University, 8 Huizhan Avenue, Renqiu, Hebei Province 062552, People’s Republic of China
推荐引用方式(GB/T 7714)：
Liang Jun-Li,Ren Xiao-Cang,Lin Qiang.Treating advanced non-small-cell lung cancer in Chinese patients: focus on icotinib[J].ONCOTARGETS AND THERAPY.2014,7:761-769.doi:10.2147/OTT.S49233.
APA：
Liang, Jun-Li,Ren, Xiao-Cang&Lin, Qiang.(2014).Treating advanced non-small-cell lung cancer in Chinese patients: focus on icotinib.ONCOTARGETS AND THERAPY,7,
MLA：
Liang, Jun-Li,et al."Treating advanced non-small-cell lung cancer in Chinese patients: focus on icotinib".ONCOTARGETS AND THERAPY 7.(2014):761-769

相关文献

[1]晚期非小细胞肺癌患者恶性胸水中表皮生长因子受体的突变检测 [2]晚期非小细胞肺癌 EGFR-TKI 获得性耐药机制 [3]To Investigate the Prognostic Factors and the Significance of TKI in Advanced NSCLC with Wild-Type EGFR [4]A Study of Apatinib Plus EGFR-TKI as First Line Treatment in Patients With Non-squamous NSCLC Harboring EGFR Mutations [5]Cigarette Smoke Extract Exposure Induces EGFR-Tki Resistance In EGFR-Mutated Nsclc Via Mediating Src Activation And Emt [6]Befotertinib for patients with pretreated EGFR T790M mutated locally advanced or metastatic NSCLC: Final overall survival results from a phase 2 trial [7]肺癌治疗中EGFR-TKI耐药与PD-L1表达的关系 [8]A Phase 2 Study of Befotertinib in Patients with EGFR T790M Mutated NSCLC after Prior EGFR TKIs [9]Efficacy and Safety of Limertinib (ASK120067) in Patients With Locally Advanced or Metastatic EGFR Thr790Met-Mutated NSCLC: A Multicenter, Single-Arm, Phase 2b Study. [10]以恶性胸腔积液为主要表现的EGFR T790M突变型肺腺癌1例及文献复习

资源点击量：39770 今日访问量：0 总访问量：1333 更新日期：2025-05-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 河北医科大学第四医院 技术支持：重庆聚合科技有限公司 地址：河北省石家庄市健康路12号